Sionna Therapeutics (NASDAQ:SION) Releases Earnings Results, Misses Estimates By $0.70 EPS

Sionna Therapeutics (NASDAQ:SION) issued its quarterly earnings results on Thursday. The company reported ($3.38) EPS for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70), Zacks reports.

Sionna Therapeutics Stock Down 3.1 %

Shares of SION stock opened at $13.88 on Thursday. Sionna Therapeutics has a 12 month low of $13.20 and a 12 month high of $25.19.

Analysts Set New Price Targets

A number of research analysts recently commented on SION shares. Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price target on the stock. Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, TD Cowen started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating on the stock.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.